Home>
Specialty Care>
HIV/AIDS>
New Drugs

New Drugs

Physician-authored summaries on the latest research on new drugs, editorials on new drugs, and perspectives on new drugs - drawn from the top medical journals.

You searched for: new drugs Items 1 to 20 of 39 results

Sort by:

Relevance
Date

New Drugs
- September 1, 2003
- Paul E. Sax, MD
Several industry-supported studies provide information on new drugs in various stages of development, including the PIs tipranavir, TMC-114, and 908 (the amprenavir prodrug), and the NRTI SPD754.
- Related Searches: aplaviroc, chemokine (c-c motif) receptor 5, darunavir, efavirenz, hiv, lamivudine, lopinavir/ritonavir, maraviroc, reverse transcriptase inhibitors, reverset, ritonavir, tenofovir, vicriviroc, zidovudine
New Drugs
- September 14, 2005
- Judith Feinberg, MD
CCR5 antagonists created quite a buzz at IAS: Several are entering phase III trials and could be available in the next 2 to 3 years.
- Related Searches: aplaviroc, chemokine (c-c motif) receptor 5, darunavir, efavirenz, hiv, lamivudine, lopinavir/ritonavir, maraviroc, reverse transcriptase inhibitors, reverset, ritonavir, tenofovir, vicriviroc, zidovudine
Therapeutic Decision Making in 1997: Roundtable Discussion of Five Cases
- February 1, 1997
In today's extremely dynamic therapeutic environment, care of the individual patient is more complex than ever. Practitioners feel compelled to use very new drugs in . . .
Promising New Agents on the Horizon
- March 1, 2002
- Judith Feinberg, MD
In several presentations at the 41st ICAAC, researchers reported promising, but mostly preliminary, data on new drugs in all 3 antiretroviral classes.
Opportunistic Infections: TB, HIV, and XDR TBFree!
- March 10, 2008
- Gerald H. Friedland, MD
Data presented at the 15th Retrovirus Conference highlighted the importance of strengthening airborne infection-control practice and relying less on hospital TB care, particularly in resource-limited settings.
- Related Searches: acquired immunodeficiency syndrome, africa south of the sahara, hiv, multidrug-resistant tuberculosis, tuberculosis, tuberculosis and hiv, tuberculosis, extensively drug-resistant
Clinical Benefit of Continuing a Failing ART Regimen in AIDS PatientsFree!
- January 14, 2008
- Keith Henry, MD
In a large study of patients with CD4 counts <200 cells/mm3, the risk for a new AIDS-defining event was 22% lower during periods of virologic failure on ART than during treatment interruptions.
- Covering:
  - Kousignian I et al., Clin Infect Dis 2008 Jan 15; 46:296.
- Related Searches: acquired immunodeficiency syndrome, anti-retroviral agents, drug holiday, hiv
Top HIV/AIDS Stories of 2007Free!
- December 28, 2007
- Paul E. Sax, MD
A perspective on the year’s most important stories in HIV medicine
- Related Searches: abacavir sulfate, acquired immunodeficiency syndrome, aids vaccines, antiretroviral therapy, highly active, antiviral agents, darunavir, elvitegravir , etravirine, hiv, hiv integrase inhibitors, hiv screen, lopinavir, male circumcision, maraviroc, multidrug-resistant hiv, raltegravir
Updated Antiretroviral Treatment Guidelines from DHHS and EACSFree!
- December 10, 2007
- Carlos del Rio, MD
The latest guidelines include new recommendations on resistance testing, earlier initiation of therapy, and use of HLA B*5701 testing in patients considering abacavir.
- Related Searches: abacavir sulfate, anti-retroviral agents, atazanavir, drug resistance, drug resistance, viral, guidelines, hiv, hla-b5701, lamivudine, maraviroc, multidrug-resistant hiv, ritonavir, tenofovir, zidovudine
Raltegravir, a New HIV Integrase InhibitorFree!
- October 22, 2007
- Rajesh T. Gandhi, MD
Because raltegravir inhibits a novel viral target, even HIV that is resistant to other antiretroviral-medication classes is sensitive to this drug.
- Related Searches: anti-retroviral agents, hiv, integrase inhibitors, raltegravir
Two Boosted PIs Are Not Better Than One
- August 30, 2007
- Sonia Nagy Chimienti, MD
In a retrospective analysis, salvage regimens that contained two full-dose PIs plus ritonavir had similar virologic efficacy to those that contained one boosted PI.
- Covering:
  - Petersen ML et al., AIDS 2007 Jul 31; 21:1547-54.
- Related Searches: anti-retroviral agents, hiv, protease inhibitor, ritonavir, salvage therapy, viral load result
Viral Rebound Rates Decrease over Time in Suppressed Patients
- August 6, 2007
- Keith Henry, MD
In a U.K.-based cohort study, viral rebound rates fell over time among patients achieving plasma HIV RNA levels ≤50 copies/mL; after 4 years of continuous suppression, rates were similar in patients with and without a history of treatment failure.
- Covering:
  - Benzie AA et al., AIDS 2007 Jul 11; 21:1423-30.
- Related Searches: hiv, hiv rna rebound, treatment failure, virus replication
New Classes, New Agents: Changing the Paradigm of Antiretroviral Treatment?Free!
- April 2, 2007
- Judith Feinberg, MD
Raltegravir (the first integrase inhibitor) and maraviroc (the first CCR5 inhibitor) are both effective and well tolerated in highly treatment-experienced patients.
- Related Searches: anti-retroviral agents, hiv, integrase inhibitors, maraviroc, raltegravir
Expanded HIV Treatment in Resource-Poor CountriesFree!
- December 29, 2006
Initial concerns that antiretroviral therapy would be less effective in resource-poor settings ― or that patients there would be less adherent ― appear to be unfounded.
- Related Searches: anti-retroviral agents, hiv, lamivudine, nevirapine, patient compliance, poverty, stavudine
Promising New Options for Treatment-Experienced PatientsFree!
- December 29, 2006
Even triple-class–experienced patients can achieve virologic suppression with some of the new agents now available.
- Related Searches: anti-retroviral agents, darunavir, etravirine, hiv, integrase inhibitors, maraviroc, mk-0518, protease inhibitor, reverse transcriptase inhibitors, salvage therapy
A Role for Foscarnet in HIV?
- October 16, 2006
- Helmut Albrecht, MD
Results were promising with this pyrophosphate analogue, but the availability of newer drugs in other classes might obviate the need to use foscarnet as salvage therapy.
- Covering:
  - Canestri A et al., Antivir Ther 2006; 11:561-6.
- Related Searches: cytomegalovirus, cytomegalovirus infection, darunavir, etravirine, foscarnet, hiv, human herpesvirus 8, integrase inhibitors, maraviroc, mk-0518, salvage therapy, stavudine, tenofovir, tipranavir, zidovudine
Mortality Rates in the First Year of Treatment in Low- Versus High-Income Countries
- April 12, 2006
- Keith Henry, MD
Patients starting potent antiretroviral therapy in low-income countries have similar rates of virologic suppression and immunologic recovery as patients in high-income counties, but they still have higher initial mortality rates.
- Covering:
  - The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups., Lancet 2006 Mar 11; 367:817-24.
  - , Lancet 2006 Mar 11; 367:789.
  - Ford N and Darder M., Lancet 2006 Mar 11; 367:794-5.
- Related Searches: antiretroviral therapy, highly active, hiv
HIV Drug Resistance in Europe
- September 28, 2005
- Charles B. Hicks, MD
Two new studies suggest that 10% of treatment-naive patients in Europe — and 20% of treated patients in the U.K. specifically — have resistance to HIV drugs.
- Covering:
  - Wensing AMJ et al., J Infect Dis 2005 Sep 15; 192:958-66.
  - UK Collaborative Group on HIV Drug Resistance., J Infect Dis 2005 Sep 15; 192:967-73.
- Related Searches: anti-retroviral agents, CATCH, drug resistance, europe, hiv, reverse transcriptase inhibitors, sexually transmitted diseases
FDA Approval: Tipranavir
- June 29, 2005
Tipranavir (Aptivus), a nonpeptidic PI with activity against many PI-resistant viruses, was given accelerated approval by the FDA on June 22, 2005. The drug must . . .
- Related Searches: hiv, protease inhibitor, tipranavir
Report from the 12th Retrovirus Conference
- March 21, 2005
This year's Retrovirus Conference returned to Boston, and despite predictably wintry weather, the premier scientific HIV meeting again attracted researchers and clinicians from all over . . .
- Related Searches: acquired immunodeficiency syndrome, aids vaccines, anti-retroviral agents, drug holiday, drug resistance, hepatitis, hepatitis c, hepatitis c virus, hiv, hiv infection syndrome, acute, hiv transmission, lipodystrophy, patient compliance, poverty, salvage therapy, tuberculosis
Meeting Report from the XV International AIDS Conference
- September 1, 2004
The XV International AIDS Conference was held in Bangkok, Thailand from July 11 to 14, under the banner "Access for All." The conference was the . . .